Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of SKLB1028 on Midazolam PK in Healthy Subjects
NCT05070195Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruserontinib in acute myeloid leukemia (AML), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Maximum Concentration at Day 3, Area Under the Concentration-Time Curve from 0 to last measurable concentration at Day 3 and 1 more. Started Jun 2021; status: completed.
02
Drugs
ruserontinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05070195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070195.